Drugs / PBK_L1704
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05509868 | Jul 2022 → Feb 2025 | — | Pharmbio Korea Co., Ltd. | Completed | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBK_L1704 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05509868 ↗ |